Fluralaner is a novel isoxazoline-class broad-spectrum insecticide. Its mechanism of action involves interfering with gamma-aminobutyric acid (GABA)-gated chloride channels, blocking neuronal chloride ion channels, thereby causing excessive excitation and convulsions in insects. This mechanism of action makes it remarkably effective in both agricultural pest control and animal parasite treatment.
Fluralaner was originally developed by Nissan Chemical Industries, Ltd. in 2004 and received international patent authorization in 2005. Its chemical structure is 4-[5-(3,5-dichlorophenyl)-4,5-dihydro-5-(trifluoromethyl)-1H-isoxazol-3-yl]-2-methyl-N-[2-oxo-2-(2,2,2-trifluoroethyl)acetamido]benzamide, with the molecular formula C22H17Cl2F6N3O3 and a molecular weight of 558.2651. Its crystalline form is a white to pale yellow powder, insoluble in water but soluble in organic solvents such as dimethyl sulfoxide (DMSO).
Unique Target Mechanism
The development of Fluralaner stems from its unique target mechanism of action—it acts on the AM1 site of GABA-gated chloride channels rather than the conventional N-carboxamide (NCA) site. This characteristic means it exhibits no cross-resistance with cyclodiene, phenylpyrazole, or macrocyclic lactone insecticides, while demonstrating low toxicity and high safety for mammals and non-target organisms (such as zebrafish and avian species).
Agricultural Applications
In agriculture, Fluralaner has been proven to possess highly efficient insecticidal activity against a variety of pests, including ticks, lice, Hemiptera, and Diptera. Its efficacy is significant, and it demonstrates effective resistance management capability against multiple drug-resistant pests. For example, Fluralaner's inhibitory effect on the GABA receptor of the housefly (Musca domestica) is 17 times stronger than on the glutamate receptor, demonstrating its high selectivity for the target.
Veterinary Applications
In veterinary medicine, Fluralaner is widely used for the treatment of ectoparasites in dogs, cats, and chickens, such as fleas and ticks. Its commercial forms include oral chewable tablets (e.g., Bayer Bravecto) and topical spot-on solutions, characterized by rapid absorption and sustained efficacy—a single administration maintains therapeutic levels in the body for 12 weeks or more. Additionally, Fluralaner demonstrates highly efficient insecticidal activity against various parasites, such as canine demodicosis (Demodex spp.) and cat fleas (Ctenocephalides spp.), with low toxicity to non-target species and a high safety profile.
Stereochemistry and Activity
The stereochemical properties of Fluralaner also play a critical role in its activity. Studies have shown that the (S)-enantiomer of Fluralaner exhibits significantly higher insecticidal activity than the (R)-enantiomer, with activity 33 to 39 times greater. This difference may be related to the binding affinity and stability of the (S)-enantiomer with the GABA receptor.
Safety and Future Prospects
Despite Fluralaner's broad application prospects in agriculture and veterinary medicine, its long-term effects on the environment and human health still require further study. For instance, there have been reports that Fluralaner may exert toxic effects on certain non-target species, necessitating caution during use. Furthermore, cost reduction and process optimization for industrial-scale production remain key focuses for future research.
As a novel isoxazoline-class insecticide, Fluralaner has attracted significant attention due to its unique target mechanism, high selectivity, and broad-spectrum insecticidal activity. Its application prospects in agriculture and veterinary medicine are extensive, but further research on its environmental and health impacts is needed to ensure safety and sustainability.
Chemical Properties
Fluralaner Structural Formula